Andexanet Alfa在因子Xa抑制剂相关脑出血中临床意义的模拟研究
本研究基于单中心603例(55例使用FXai)接受PCC治疗的FXai相关脑出血患者数据,通过模拟分析Andexanet Alfa在不同止血效果下的潜在临床影响。结果显示,当止血不充分概率降低33%和50%时,不良结局绝对风险降低分别为4.9%和7.4%,对应NNT为21和14。研究者认为即使乐观模拟也需谨慎权衡成本与获益,推荐使用前需安慰剂对照随机试验。
要点
- 止血不充分与3个月不良结局强相关(OR 4.5, 95%CI 2.0-9.9)。
- 模拟止血不充分概率降低33%时,绝对风险降低4.9%,NNT=21。
- 模拟降低50%时,绝对风险降低7.4%,NNT=14。
核心结论
- 即使乐观模拟的止血效果也提示Andexanet Alfa的成本与潜在获益需仔细权衡。
- 需安慰剂对照随机试验才能明确推荐其使用。
研究设计与样本
- 模拟研究,基于单中心接受PCC治疗的FXai相关ICH患者数据(n=603,其中55例使用FXai)。
- 通过多变量回归模型预测止血不充分概率和3个月不良结局(mRS 4-6),并用bootstrapping模拟不同止血改善程度。
主要发现
- 预测止血不充分的AUC为0.78,预测不良结局的AUC为0.78。
- 止血不充分与不良结局相关(OR 4.5, 95%CI 2.0-9.9),FXai患者中止血不充分发生率为11.4%。
- 模拟FXai患者中,止血不充分概率降低33%时,不良结局绝对风险降低4.9%(95%CI 1.3%-7.8%)。
- 止血不充分概率降低50%时,绝对风险降低7.4%(95%CI 2.0%-11.9%)。
关键数值与推荐
- 模拟降低33%时,NNT=21,累计成本$519,750。
- 模拟降低50%时,NNT=14,累计成本$346,500。
临床怎么用
- 临床决策中应结合成本与潜在获益谨慎考虑Andexanet Alfa的使用。
- 目前证据尚不足以明确推荐Andexanet Alfa,需等待随机试验结果。
局限性
- 为模拟研究,基于单中心数据,结果需外部验证。
- 止血效果改善幅度为假设模拟,非实际观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Andexanet alfa was recently approved as a reversal agent for the factor Xa inhibitors (FXais) apixaban and rivaroxaban, but its impact on long-term outcomes in FXai-associated intracerebral hemorrhage (ICH) is unknown. We aimed to explore potential clinical implications of andexanet alfa in FXai-associated ICH in this simulation study. METHODS: We simulated potential downstream implications of andexanet alfa across a range of possible hemostatic effects using data from a single center that treats FXai-associated ICH with prothrombin complex concentrate (PCC). We determined baseline probabilities of inadequate hemostasis across patients taking FXai and those not taking FXai via multivariable regression models and then determined the probabilities of unfavorable 3-month outcome (modified Rankin Scale score 4-6) using models comprising established predictors and each patient's calculated probability of inadequate hemostasis. We applied bootstrapping with model parameters from this derivation cohort to simulate a range of hemostatic improvements and corresponding outcomes and then calculated absolute risk reduction (relative to PCC) and projected number needed to treat (NNT) to prevent 1 unfavorable outcome. RESULTS: Training models using real-world patients (n = 603 total, 55 on FXai) had good accuracy in predicting inadequate hemostasis (area under the curve [AUC] 0.78) and unfavorable outcome (AUC 0.78). Inadequate hemostasis was strongly associated with unfavorable outcome (odds ratio 4.5, 95% confidence interval [CI] 2.0-9.9) and occurred in 11.4% of patients taking FXai. Across simulated patients taking FXai comparable to those in A Study in Participants With Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors (ANNEXA-4) study, predicted absolute risk reduction of unfavorable outcome was 4.9% (95% CI 1.3%-7.8%) when the probability of inadequate hemostasis was reduced by 33% and 7.4% (95% CI 2.0%-11.9%) at 50% reduction, translating to projected NNT of 21 (cumulative cost $519,750) and 14 ($346,500), respectively. DISCUSSION: Even optimistic simulated hemostatic effects suggest that the costs and potential benefits of andexanet alfa should be carefully considered. Placebo-controlled randomized trials are needed before its use can definitively be recommended.
引用
- Chuck CC, Kim D, Kalagara R, et al. Modeling the Clinical Implications of Andexanet Alfa in Factor Xa Inhibitor-Associated Intracerebral Hemorrhage. Neurology. 2021. PMID: 34556569. doi:10.1212/WNL.0000000000012856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。